3,4-Dihydroxyacetophenone alleviates lipopolysaccharide-induced acute lung injury as a potential anti-inflammatory and anti-oxidative agent

doi:10.5246/jcps.2021.12.082

Abstract

Abstract:

Enhanced inflammatory response and oxidative stress cause acute lung injury (ALI). Controlling inflammation and oxidation can ameliorate ALI. In the present study, we aimed to determine whether 3,4-Dihydroxyacetophenone (compound 1) could ameliorate lipopolysaccharide (LPS)-induced ALI by suppressing inflammation and oxidation. In this study, compound 1 reduced LPS-induced inflammatory cytokines and oxidative stress in RAW 264.7 cells. Moreover, compound 1 suppressed the expression of inflammatory protein p65, inhibited IkBα phosphorylation, decreased the nuclear translocation of p65, and increased the expressions of anti-oxidative protein nuclear factor erythroid 2-related factor 2 (Nrf-2) and heme oxygenase-1 (HO-1), which was reduced by LPS, in leukemia cells in mouse macrophage (RAW 264.7) cells. Furthermore, compound 1 could also ameliorate LPS-induced ALI in vivo, with a reduction of inflammatory cytokines, oxidative stress, and nuclear factor-kappa B (NF-κB) signaling pathway activation. This study emphasized the anti-inflammatory and anti-oxidative activities of compound 1, which could be a valuable therapeutic agent against ALI.

Key words: 3,4-Dihydroxyacetophenone, Acute lung injury, Anti-inflammatory, Antioxidant

Supporting:

Yinyan Xu, Min Zhu, Kaiheng Zhou, Taotao Song, Lili Huang. 3,4-Dihydroxyacetophenone alleviates lipopolysaccharide-induced acute lung injury as a potential anti-inflammatory and anti-oxidative agent[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(12): 956-968.

Figures/Tables 6

References 34

[1]	Gao, X.L.; Meng X.B.; Jiang Y.M.; Li, Z.J.; Ye, J. The protective effects of thalidomide derivative ZSN-12 on acute lung injury. J. Chin. Pharm. Sci. 2013, 22, 435–440.
[2]	Lin, Y.T.; Qiu, D.P.; Huang, L.L.; Zhang, S.S.; Song, C.J.; Wang, B.B.; Wu, J.Z.; Chen, C.S. A novel chalcone derivative, L2H17, ameliorates lipopolysaccharide-induced acute lung injury via upregulating HO-1 activity. Int. Immunopharmacol. 2019, 71, 100–108.
[3]	Dorward, D.A.; Lucas, C.D.; Doherty, M.K.; Chapman, G.B.; Scholefield, E.J.; Conway Morris, A.; Felton, J.M.; Kipari, T.; Humphries, D.C.; Robb, C.T.; Simpson, A.J.; Whitfield, P.D.; Haslett, C.; Dhaliwal, K.; Rossi, A.G. Novel role for endogenous mitochondrial formylated peptide-driven formyl peptide receptor 1 signalling in acute respiratory distress syndrome. Thorax. 2017, 72, 928–936.
[4]	Eltzschig, H.K.; Bratton, D.L.; Colgan, S.P. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat. Rev. Drug Discov. 2014, 13, 852–869.
[5]	Hu, Y.; Lou, J.; Mao, Y.Y.; Lai, T.W.; Liu, L.Y.; Zhu, C.; Zhang, C.; Liu, J.; Li, Y.Y.; Zhang, F.; Li, W.; Ying, S.M.; Chen, Z.H.; Shen, H.H. Activation of MTOR in pulmonary epithelium promotes LPS-induced acute lung injury. Autophagy. 2016, 12, 2286–2299.
[6]	Takashima, K.; Matsushima, M.; Hashimoto, K.; Nose, H.; Sato, M.; Hashimoto, N.; Hasegawa, Y.; Kawabe, T. Protective effects of intratracheally administered quercetin on lipopolysaccharide-induced acute lung injury. Respir. Res. 2014, 15, 150.
[7]	Wu, J.Z.; Li, J.L.; Cai, Y.P.; Pan, Y.; Ye, F.Q.; Zhang, Y.L.; Zhao, Y.J.; Yang, S.L.; Li, X.K.; Liang, G. Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents. J. Med. Chem. 2011, 54, 8110–8123.
[8]	Meng, L.; Li, L.Y.; Lu, S.; Li, K.; Su, Z.B.; Wang, Y.Y.; Fan, X.D.; Li, X.Y.; Zhao, G.Q. The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways. Mol. Immunol. 2018, 94, 7–17.
[9]	Imai, Y.; Kuba, K.; Neely, G.G.; Yaghubian-Malhami, R.; Perkmann, T.; van Loo, G.; Ermolaeva, M.; Veldhuizen, R.; Leung, Y.H.C.; Wang, H.L.; Liu, H.L.; Sun, Y.; Pasparakis, M.; Kopf, M.; Mech, C.; Bavari, S.; Peiris, J.S.M.; Slutsky, A.S.; Penninger, J.M. Identification of oxidative stress and toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008, 133, 235–249.
[10]	Pei, X.F.; Zhang, X.J.; Chen, H.M. Bardoxolone treatment alleviates lipopolysaccharide (LPS)-induced acute lung injury through suppressing inflammation and oxidative stress regulated by Nrf2 signaling. Biochem. Biophys. Res. Commun. 2019, 516, 270–277.
[11]	Tian, C.; Chen, X.; Chang, Y.; Wang, R.; Ning, J.; Cui, C.; Liu, M. Abutilon theophrastiThe regulatory effect of flavonoids extracted from leaves on gene expression in LPS-induced ALI mice via the NF-κB and MAPK signaling pathways.Pharm. Biol. 2019, 57, 514–518.
[12]	Wang, J.B.; Huang, L.L.; Cheng, C.C.; Li, G.; Xie, J.W.; Shen, M.Y.; Chen, Q.; Li, W.L.; He, W.F.; Qiu, P.H.; Wu, J.Z. Design, synthesis and biological evaluation of chalcone analogues with novel dual antioxidant mechanisms as potential anti-ischemic stroke agents. Acta Pharm. Sin. B. 2019, 9, 335–350.
[13]	Zhang, H.Y.; Sha, J.C.; Feng, X.J.; Hu, X.Y.; Chen, Y.P.; Li, B.; Fan, H.G. Dexmedetomidine ameliorates LPS induced acute lung injury via GSK-3β/STAT3-NF-κB signaling pathway in rats. Int. Immunopharmacol. 2019, 74, 105717.
[14]	Zhao, B.; Gao, W.W.; Gao, X.; Leng, Y.; Liu, M.; Hou, J.B.; Wu, Y. Sulforaphane attenuates acute lung injury by inhibiting oxidative stress via Nrf2/HO-1 pathway in a rat sepsis model. Int. J. Clin. Exp. Pathol. 2017, 10, 9021–9028.
[15]	Yang, H.; Lv, H.; Li, H.; Ci, X.; Peng, L. Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-κB pathways. Cell Commun. Signal. 2019, 17, 62.
[16]	Meng, X.L.; Hu, L.; Li, W.Q. Baicalin ameliorates lipopolysaccharide-induced acute lung injury in mice by suppressing oxidative stress and inflammation via the activation of the Nrf2-mediated HO-1 signaling pathway. Naunyn Schmiedeberg's Arch. Pharmacol. 2019, 392, 1421–1433.
[17]	Hu, Q.; Wang, Q.; Han, C.G.; Yang, Y. Sufentanil attenuates inflammation and oxidative stress in sepsis-induced acute lung injury by downregulating KNG1 expression. Mol. Med. Rep. 2020, 22, 4298–4306.
[18]	Zhang, Y.L.; Liang, D.D.; Dong, L.L.; Ge, X.T.; Xu, F.L.; Chen, W.B.; Dai, Y.R.; Li, H.M.; Zou, P.; Yang, S.L.; Liang, G. Anti-inflammatory effects of novel curcumin analogs in experimental acute lung injury. Respir. Res. 2015, 16, 1–13.
[19]	Wang, J.; Liu, Y.T.; Xiao, L.; Zhu, L.P.; Wang, Q.J.; Yan, T.H. Anti-inflammatory effects of apigenin in lipopolysaccharide-induced inflammatory in acute lung injury by suppressing COX-2 and NF-kB pathway. Inflammation. 2014, 37, 2085–2090.
[20]	Manicone, A.M. Role of the pulmonary epithelium and inflammatory signals in acute lung injury. Expert. Rev. Clin. Immunol. 2009, 5, 63–75.
[21]	Goodman, R.B.; Pugin, J.; Lee, J.S.; Matthay, M.A. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev. 2003, 14, 523–535.
[22]	Huang, L.L.; Wang, J.B.; Chen, L.P.; Zhu, M.; Wu, S.B.; Chu, S.H.; Zheng, Y.T.; Fan, Z.L.; Zhang, J.F.; Li, W.L.; Chen, D.H.; Yang, X.F.; Wang, S.C.; Qiu, P.H.; Wu, J.Z. Design, synthesis, and evaluation of NDGA analogues as potential anti-ischemic stroke agents. Eur. J. Med. Chem. 2018, 143, 1165–1173.
[23]	Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3, 1101–1108.
[24]	Feng, G.; Sun, B.; Liu, H.X.; Liu, Q.H.; Zhao, L.; Wang, T.L. EphA2 antagonism alleviates LPS-induced acute lung injury via Nrf2/HO-1, TLR4/MyD88 and RhoA/ROCK pathways. Int. Immunopharmacol. 2019, 72, 176–185.
[25]	El Sayed, N.S.; Sayed, A.S. Protective effect of methylene blue on TNBS-induced colitis in rats mediated through the modulation of inflammatory and apoptotic signalling pathways. Arch. Toxicol. 2019, 93, 2927–2942.
[26]	Chow, C.W.; Herrera Abreu, M.T.; Suzuki, T.; Downey, G.P. Oxidative stress and acute lung injury. Am. J. Respir. Cell Mol. Biol. 2003, 29, 427–431.
[27]	Sun, S.C. The non-canonical NF-κB pathway in immunity and inflammation. Nat. Rev. Immunol. 2017, 17, 545–558.
[28]	Hoesel, B.; Schmid, J.A. The complexity of NF-κB signaling in inflammation and cancer. Mol. Cancer. 2013, 12, 86.
[29]	Jamilloux, Y.; El Jammal, T.; Vuitton, L.; Gerfaud-Valentin, M.; Kerever, S.; Sève, P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun. Rev. 2019, 18, 102390.
[30]	Liu, C.Y.; Sun, J.; Xue, F.; Yi, Y.C.; Han, A.Q. Effect of 3, 4-dihydroxyacetophenone on endothelial dysfunction in streptozotocin-induced rats with type 2 diabetes. J. Cardiovasc. Pharmacol. 2015, 65, 22–27.
[31]	Hui, Z.G.; Zhou, X.W.; Li, R.J. Effect of 3,4-dihydroxyacetophenone on endothelial dysfunction in obese rats. Pharm. Biol. 2015, 53, 1149–1154.
[32]	Fan, H.N.; Chen, W.; Zhu, J.S.; Zhang, J.; Peng, S.Q. Toosendanin alleviates dextran sulfate sodium-induced colitis by inhibiting M1 macrophage polarization and regulating NLRP3 inflammasome and Nrf2/HO-1 signaling. Int. Immunopharmacol. 2019, 76, 105909.
[33]	Duan, J.X.; Yang, Z.; Huang, J.; Zhu, Y.; Zhao, H.L.; Unwith, S.; Gao, X.; Lu, K.Z.; Ning, J.L. Inhibition of tyrosine kinases protects against lipopolysaccharide-induced acute lung injury by preventing nuclear export of Nrf2. J. Cell Biochem. 2019, 120, 12331–12339.
[34]	Zhang, D.; Liu, J.; Wang, L.; Wang, J.; Li, W.; Zhuang, B.; Hou, J.; Liu, T. Effects of 3, 4-dihydroxyacetophenone on the hypercholesterolemia-induced atherosclerotic rabbits. Biol. Pharm. Bull. 2013, 36, 733–740.